Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The legal action follows a March 2026 report by Culper Research, which accused the biotechnology firm of inflating its revenue figures. The research firm alleged that ADMA Biologics utilized channel stuffing—offering rebates and extended payment terms to distributors—to create the appearance of 20% growth when, according to the report, the company actually faced a 3% revenue decline. The lawsuit further claims that the company failed to disclose a related-party transaction and lacked sufficient internal oversight.

Following the publication of these allegations, ADMA Biologics shares fell from $13.59 to $9.63 over two trading days, representing a 29% decline in value. Faruqi & Faruqi, LLP, the firm representing the class, is currently evaluating claims from shareholders who incurred losses during the specified period. While investors have until August 10 to move the court for lead plaintiff status, those who opt not to lead the case remain eligible to participate in any potential settlement or recovery. The firm is also soliciting information from former employees and whistleblowers regarding the company’s internal practices.